Antibiotic compounds
View Patent ↗The present invention provides methods for identifying (3-amino-2-oxo-azetidin-1-yl) acetic acid derivatives with anti-PBP2a activity. The method involves the selection of RNA biocatalysts that promote the formation of (3-amino-2-oxo-azetidin-1-yl) acetic acid derivatives with anti-PBP2a activity from component reactants. The invention also provides novel (3-amino-2-oxo-azetidin-1-yl) acetic acid derivatives with anti-PBP2a activity identified by these methods. The invention also provides RNA biocatalysts that are capable of catalyzing the formation of (3-amino-2-oxo-azetidin-1-yl) acetic acid derivatives from component reactants.
1. A compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein: wherein X is CH 2 , NH, or O;
R 1 , is selected from the group consisting of C 1 –C 20 alkyl, C 2 –C 20 akenyl, C 2 –C 20 alkynyl, OR 6 , C(O)R 6 , carboalkoxyalkyl, a heterocyclyl selected from the group consisting of furanyl, pyridyl, pyrrolyl and imidazolyl, aromatic hydrocarbon and cycloalkyl, all of which may be optionally substituted by one or more of the groups selected from C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, cycloalkyl, a heterocyclyl selected from the group consisting of furanyl, pyridyl, pyrrolyl and imidazolyl, aryl, halogen, cyano, nitro, amino, alkylamino, dialkylamino, aminoalkyl, dialkylaminoalkyl, arylamino, aminoaryl, alkylaminoaryl, alkylcarbonylamino, carboxy, carboxyalkyl, C(O)R 6 , OR 6 , CONR 6, wherein all said substituents may be optionally substituted with one or more selected from the group consisting of halogen, C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, cycloalkyl, OR 6 , C(O)R 6 , carboalkoxyalkyl, cyano, and nitro; R 2 , R 3 , R 4 and R 5 are independently selected from the group consisting of hydrogen, C 1 –C 20 alkyl, C 2 –C 20 akenyl, C 2 –C 20 alkynyl, OR 6 , C(O)R 6 , carboalkoxyalkyl, a heterocyclyl selected from the group consisting of furanyl, pyridyl, pyrrolyl and imidazolyl, aromatic hydrocarbon and cycloalkyl, all of which may be optionally substituted by one or more of the groups selected from C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, cycloalkyl, a heterocyclyl selected from the group consisting of furanyl, pyridyl, pyrrolyl and imidazolyl, aryl, halogen, cyano, nitro, amino, alkylamino, dialkylamino, aminoalkyl, dialkylaminoalkyl, arylamino, aminoaryl, alkylaminoaryl, alkylcarbonylamino, carboxy, carboxyalkyl, C(O)R 6 , OR 6 , CONR 6, wherein all said substituents may be optionally substituted with one or more selected from the group consisting of halogen, C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, cycloalkyl, OR 6 , C(O)R 6 , carboalkoxyalkyl, cyano, and nitro; and
R 6 is selected from the group consisting of hydrogen, halogen, C 1 –C 20 alkyl, aromatic hydrocarbon, and alkylaryl, wherein all said substituents may be optionally substituted by one or more carboalkoxy, amino, hydroxyl, carboxyl, lower alkyl, lower alkenyl, lower alkynyl, halo, cyano, nitro, carboxyalkyl, and unsubstituted carbamoyl.
2. A monobactam with anti-PBP2a activity, wherein said monobactam is prepared by the process comprising:
a) providing a monobactam core alkyne having the structure
wherein R 1 is selected from the group consisting of:
R 2 is selected from the group consisting of:
R 3 and R 4 are independently selected from the group consisting of hydrogen, C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, OR 5 , C(O)R 5 , carboalkoxyalkyl, heterocyclyl, aromatic hydrocarbon and cycloalkyl, all of which may be optionally substituted by one or more of the groups selected from C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, cycloalkyl, a heterocyclyl selected from the group consisting of furanyl, pyridyl, pyrrolyl and imidazolyl, aryl, halogen, cyano, nitro, amino, alkylamino, dialkylamino, aminoalkyl, dialkylaminoalkyl, arylamino, aminoaryl, alkylaminoaryl, alkylcarbonylamino, carboxy, carboxyalkyl, C(O)R 5 , OR 5 , CONR 5, wherein all said substituents may be optionally substituted with one or more selected from the group consisting of halogen, C 1 –C 20 alkyl, C 2 –C 20 alkenyl, C 2 –C 20 alkynyl, cycloalkyl, OR 5 , C(O)R 5 , carboalkoxyalkyl, cyano, and nitro; and
R 5 is selected from the group consisting of hydrogen, halogen, C 1 –C 20 alkyl, aromatic hydrocarbon, and alkylaryl, wherein all said substituents may be optionally substituted by one or more carboalkoxy, amino, hydroxyl, carboxyl, lower alkyl, lower alkenyl, lower alkynyl, halo, cyano, nitro, carboxyalkyl, and unsubstituted carbamoyl;
b) reacting said monobactam alkyne under conditions that promote cyclotrimerization with at least one alkyne selected from the group consisting of:
with the proviso that when R 1 is selected from the group consisting of:
the cyclotrimerization reaction mixture also includes at least one alkyne selected from the group consisting of:
c) performing a Diels-Alder reaction between the cyclotrimerization product of b) and a diene reactant selected from the group consisting of:
whereby a monobactam with anti-PBP2a activity may be prepared.
3. A monobactam having the formula:
or pharmaceutically acceptable salt thereof, wherein R 1 is the Diels-Alder product formed by the reaction of
with the functionality on an alkyne selected from the group consisting of:
and wherein R 2 is the functionality on an alkyne selected from the group consisting of:
4. A monobactam compound with the following formula:
wherein each n is independently 0–4;
each X is independently O, S, CH 2 or NH;
each R is independently lower alkyl optionally substituted with OR 1 , where R 1 is H or lower alkyl; and
each Z is independently H; halogen; OH; phenyl, heteroaromatic, or lower alkyl optionally substituted with one or more halogen, OH, phenyl or heteroaromatic groups.